| pubmed-article:15862755 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C0009488 | lld:lifeskim |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C0085862 | lld:lifeskim |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C1299583 | lld:lifeskim |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C0805443 | lld:lifeskim |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C1608386 | lld:lifeskim |
| pubmed-article:15862755 | lifeskim:mentions | umls-concept:C1549571 | lld:lifeskim |
| pubmed-article:15862755 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:15862755 | pubmed:dateCreated | 2005-5-2 | lld:pubmed |
| pubmed-article:15862755 | pubmed:abstractText | The prevalence of co-morbidity among elderly lymphoma patients is associated with a decrease in the use of chemotherapy. This study assessed the independent prognostic effect of co-morbidity in 1551 unselected lymphoma patients, diagnosed between 1995 and 2001 in the area of the population-based Eindhoven Cancer Registry. The prevalence of serious co-morbidity was 58% for patients with Hodgkin's disease (HD) who were over 60 years of age and 66% for patients with non-Hodgkin's lymphoma (NHL) who were over 60 years of age. The administration of chemotherapy declined in the presence of co-morbidity for elderly patients with early-stage HD and elderly patients with aggressive NHL. Co-morbidity was associated with a 10-20% decline in 5-year survival. Whether less frequent application of chemotherapy in the presence of co-morbidity is justified as far as complications, prognosis and quality of life are concerned requires further investigation. | lld:pubmed |
| pubmed-article:15862755 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15862755 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15862755 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15862755 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15862755 | pubmed:month | May | lld:pubmed |
| pubmed-article:15862755 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:15862755 | pubmed:author | pubmed-author:PetersW GWG | lld:pubmed |
| pubmed-article:15862755 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:15862755 | pubmed:author | pubmed-author:Janssen-Heijn... | lld:pubmed |
| pubmed-article:15862755 | pubmed:author | pubmed-author:CoeberghJ W... | lld:pubmed |
| pubmed-article:15862755 | pubmed:author | pubmed-author:LemmensV E... | lld:pubmed |
| pubmed-article:15862755 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15862755 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:15862755 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15862755 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15862755 | pubmed:pagination | 1051-7 | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:meshHeading | pubmed-meshheading:15862755... | lld:pubmed |
| pubmed-article:15862755 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15862755 | pubmed:articleTitle | Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. | lld:pubmed |
| pubmed-article:15862755 | pubmed:affiliation | Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. | lld:pubmed |
| pubmed-article:15862755 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15862755 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15862755 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15862755 | lld:pubmed |
